Ling Han

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

Rohit Loomba, Eric Lawitz, Parvez Mantry et al. · Hepatology · 2017 · 553 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials

Quentin M. Anstee, Eric Lawitz, Naim Alkhouri et al. · Hepatology · 2019 · 266 citations

Medicine, Internal Medicine, Pathology +17

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis

Eric Lawitz, Angie Coste, Fred Poordad et al. · Clinical Gastroenterology and Hepatology · 2018 · 215 citations

Medicine, Pharmacology, Pharmacotherapy +14

Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib

Saumya Jayakumar, Michael S. Middleton, Eric Lawitz et al. · Journal of Hepatology · 2018 · 206 citations

Medicine, Pathology, Radiology +17

A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH

Amaro Taylor‐Weiner, Harsha Pokkalla, Ling Han et al. · Hepatology · 2021 · 195 citations · Full text

Medicine, Pathology, Hepatology +16